Matthew Pauls Biography and Net Worth

Director of Soleno Therapeutics


Mr. Pauls brings more than three decades of experience in the biopharmaceutical industry. Since 2020, Mr. Pauls has served as Chair of the Board of Directors and Chief Executive Officer of Savara, Inc., a biopharmaceutical company focused on rare respiratory diseases. He is also a member of the Board of Directors at Amplo Biotechnology, a private gene therapy company focused on rare neuromuscular disorders, and Pelthos Therapeutics, a private biopharmaceutical company focused on dermatologic infectious diseases. From 2014 to 2019, Mr. Pauls was President and Chief Executive Officer and a member of the Board of Directors of Strongbridge Biopharma plc., a publicly traded rare-disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to 2014, he served as Chief Commercial Officer of Insmed, Inc., where he led both the global Commercial and CMC/Technical Operations teams. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations, and earlier in his career held senior U.S. and global commercial leadership positions at Bristol-Myers Squibb and Johnson & Johnson. In addition to his Board positions at Savara and Strongbridge, Mr. Pauls has also served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

What is Matthew Pauls' net worth?

The estimated net worth of Matthew Pauls is at least $454,545.00 as of March 28th, 2025. Mr. Pauls owns 6,500 shares of Soleno Therapeutics stock worth more than $454,545 as of April 17th. This net worth estimate does not reflect any other investments that Mr. Pauls may own. Learn More about Matthew Pauls' net worth.

How do I contact Matthew Pauls?

The corporate mailing address for Mr. Pauls and other Soleno Therapeutics executives is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. Soleno Therapeutics can also be reached via phone at (650) 213-8444 and via email at ir@soleno.life. Learn More on Matthew Pauls' contact information.

Has Matthew Pauls been buying or selling shares of Soleno Therapeutics?

Matthew Pauls has not been actively trading shares of Soleno Therapeutics during the last quarter. Most recently, Matthew Pauls sold 5,937 shares of the business's stock in a transaction on Friday, March 28th. The shares were sold at an average price of $71.55, for a transaction totalling $424,792.35. Following the completion of the sale, the director now directly owns 6,500 shares of the company's stock, valued at $465,075. Learn More on Matthew Pauls' trading history.

Who are Soleno Therapeutics' active insiders?

Soleno Therapeutics' insider roster includes Anish Bhatnagar (CEO), Patricia Hirano (Insider), Michael Huang (VP), James Mackaness (CFO), Matthew Pauls (Director), Jack Schuler (Major Shareholder), and Kristen Yen (Senior Vice President, Clinical Operations). Learn More on Soleno Therapeutics' active insiders.

Are insiders buying or selling shares of Soleno Therapeutics?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 2,510,089 shares worth more than $139,065,642.37. The most recent insider tranaction occured on April, 1st when insider Patricia C Hirano sold 3,782 shares worth more than $265,156.02. Insiders at Soleno Therapeutics own 12.3% of the company. Learn More about insider trades at Soleno Therapeutics.

Information on this page was last updated on 4/1/2025.

Matthew Pauls Insider Trading History at Soleno Therapeutics

See Full Table

Matthew Pauls Buying and Selling Activity at Soleno Therapeutics

This chart shows Matthew Pauls's buying and selling at Soleno Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Soleno Therapeutics Company Overview

Soleno Therapeutics logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More

Today's Range

Now: $69.98
Low: $68.34
High: $70.51

50 Day Range

MA: $54.36
Low: $43.68
High: $73.67

2 Week Range

Now: $69.98
Low: $36.61
High: $74.00

Volume

1,236,195 shs

Average Volume

719,103 shs

Market Capitalization

$3.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A